Cellectis S.A. (CLLS) |
|
1.58 0 (0%)
|
09-29 16:00 |
|
Open: |
1.58 |
Pre. Close: |
1.58 |
|
High:
|
1.59 |
Low:
|
1.58 |
|
Volume:
|
7,365 |
Market Cap:
|
88(M) |
|
|
|
Technical analysis |
as of: 2023-09-29 4:26:37 PM |
|
Short-term rate:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
|
Mid-term rate:
|
|
| Target: |
Six months: 2.25 One year: 2.51 |
| Support: |
Support1: 1.58 Support2: 1.31 |
| Resistance: |
Resistance1: 1.93 Resistance2: 2.15 |
| Pivot: |
1.66 |
| Moving Average: |
MA(5): 1.59 MA(20): 1.7
MA(100): 1.93 MA(250): 2.15 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 2 %D(3): 5.2 |
| RSI: |
RSI(14): 34.7 |
| 52-week: |
High: 4.03 Low: 1.58 |
| Average Vol(K): |
3-Month: 51 (K) 10-Days: 33 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CLLS ] has closed above bottom band by 16.7%. Bollinger Bands are 42.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.59 - 1.6 |
1.6 - 1.61 |
|
Low:
|
1.56 - 1.57 |
1.57 - 1.58 |
|
Close:
|
1.56 - 1.58 |
1.58 - 1.6 |
|
Company Description |
|
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France. |
Headline News |
Wed, 27 Sep 2023
Cellectis présentera des données précliniques sur des cellules ... - Zonebourse.com
Tue, 26 Sep 2023
Abeona Therapeutics Submits BLA for Groundbreaking RDEB ... - Best Stocks
Wed, 09 Aug 2023
Cellectis: Potential That Seems Perennially Unrealized (NASDAQ ... - Seeking Alpha
Thu, 03 Aug 2023
Cellectis Provides Business Updates and Preliminary Financial ... - GlobeNewswire
Fri, 28 Jul 2023
Abeona stock spikes after regulatory update on lead program - Seeking Alpha
Thu, 22 Jun 2023
Cidara stock gains on FDA fast track status for flu asset - Seeking Alpha
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
56 (M) |
| Shares Float |
39 (M) |
|
% Held by Insiders
|
12.1 (%) |
|
% Held by Institutions
|
28.4 (%) |
|
Shares Short
|
322 (K) |
|
Shares Short P.Month
|
343 (K) |
Stock Financials |
|
EPS
|
-1.63 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
1.74 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-319.8 |
|
Return on Assets (ttm)
|
-18.1 |
|
Return on Equity (ttm)
|
-62.9 |
|
Qtrly Rev. Growth
|
-26.5 |
|
Gross Profit (p.s.)
|
0.43 |
|
Sales Per Share
|
0.44 |
|
EBITDA (p.s.)
|
-1.28 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-75 (M) |
|
Levered Free Cash Flow
|
-51 (M) |
Stock Valuations |
|
PE Ratio
|
-0.97 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0.9 |
|
Price to Sales
|
3.54 |
|
Price to Cash Flow
|
-1.18 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
